Replies to post #26394 on Mymetics Corp (MYMX)

[bow-tie]

taggs.hhs.gov › Detail › Award Detail Award Information | HHS TAGGS
Jan 13, 2022 · Two independent nonhuman primate (NHP) studies demonstrated the safety and high efficacy of the combination of virosome-P1 + virosome rgp41 against repeated low-dose

https://taggs.hhs.gov/Detail/AwardDetail?arg_AwardNum=U19AI142636&arg_ProgOfficeCode=104

vaccines given by selected mucosal routes – and generate GMP vaccine for a Phase I trial to be conducted with the HVTN. Our vaccine development plans represent major advances, as the novel needle-free, solid vaccine dosage forms are cold-chain independent and will be mucosally delivered – unique aspects that make the novel virosomal vaccines especially attractive for the developing world, where the AIDS epidemic remains a serious problem.